Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue. Click for my updated look at LLY and NVO.
Eli Lilly, Novo Nordisk’s Historic GLP-1 Pricing Deals – What Investors Need To Know
view original post